Abstract:The field of rare disease therapeutics has witnessed significant growth in recent years, highlighting the need for diverse therapeutic approaches to cater to the unique needs of individuals with rare diseases. Rare disease therapies encompass a broad spectrum of interventions, including orphan medicinal products, orphan medical devices, rehabilitative therapies, and digital therapeutics, with the lines between these categories blurring. This paper covers the session of the RE (ACT)-IRDiRC Conference 2023 and delves into the landscape of orphan medical device research and development, shedding light on the challenges and opportunities in this burgeoning field. It provides a short overview of the different international legislations in the field. In addition, it highlights several exemplary orphan medical devices. The first example is an exoskeleton for boys with Duchenne Muscular Dystrophy, enabling them to maintain arm functionality and independence. Another example presented was an EEG device linked to an app detecting seizures in rare epilepsy conditions, which alerts caregivers to seizures in real-time but also facilitates objective seizure reporting for clinicians, aiding in diagnosis and treatment optimization. It also showcases the role of gamification and enabling technologies in addressing rare diseases, by showing a game designed for children with cystic fibrosis, and a telemedicine system for rehabilitation therapy. Both solutions aim to improve patients' understanding of their conditions and enhance their self-management. In conclusion, this paper underscores the critical need for patient-centric orphan and pediatric medical devices to provide therapeutic options for individuals with rare diseases. It highlights the impact of existing devices on enhancing the quality of life for rare disease patients and emphasizes the necessity for greater incentives and support for research and development in this field.

Natural History and Real‐World Data in Rare Diseases: Applications, Limitations, and Future Perspectives

Use of Real-World Data and Real-World Evidence in Rare Disease Drug Development: A Statistical Perspective

Use of real‐world evidence in regulatory decisions for rare diseases in the United States—Current status and future directions

Rare diseases, spotlighting amyotrophic lateral sclerosis, Huntington’s disease, and myasthenia gravis: Insights from landscape analysis of current research

Rare diseases: Insights from landscape analysis of current research, spotlighting amyotrophic lateral sclerosis, Huntington’s disease, and myasthenia gravis

Model‐Informed Approach Supporting Drug Development and Regulatory Evaluation for Rare Diseases

Clinical Pharmacology Applications of Real‐World Data and Real‐World Evidence in Drug Development and Approval–An Industry Perspective

Challenges of developing and conducting clinical trials in rare disorders

Use of Real‐World Evidence to Drive Drug Development Strategy and Inform Clinical Trial Design

Lessons learned from the RE(ACT) conference on medical devices for rare diseases

Human and Machine Intelligence Together Drive Drug Repurposing in Rare Diseases

The Role of Pharmacogenomics in Rare Diseases

A Descriptive Review of Global Real World Evidence Efforts to Advance Drug Discovery and Clinical Development in Amyotrophic Lateral Sclerosis

Real-world evidence for coverage determination of treatments for rare diseases

Rare and undiagnosed diseases: From disease-causing gene identification to mechanism elucidation

A rare partnership: patient community and industry collaboration to shape the impact of real-world evidence on the rare disease ecosystem

Data silos are undermining drug development and failing rare disease patients

Increase transparency and reproducibility of real‐world evidence in rare diseases through disease‐specific Federated Data Networks

Biological Network Approaches and Applications in Rare Disease Studies

Reality check: Real-world evidence to support therapeutic development in hematologic malignancies